UK Aesthetics Regulation: The October 2026 Position

As of October 2026 the UK no longer has one aesthetics regulatory position — it has three diverging ones. England still has no licensing scheme in force: the enabling power exists, the policy has been announced, but the secondary legislation has not been made. Scotland has legislated, with offences not expected to commence before September 2027. Running underneath both, the MHRA issued a product-safety warning in July 2026 about iatrogenic botulism and a continuing criminal crackdown on unlicensed and counterfeit botulinum toxins.

England: the power exists, the rules do not

Section 180 of the Health and Care Act 2022 gives the Secretary of State power to create a licensing scheme for non-surgical cosmetic procedures in England and Wales. Section 180(4) requires a consultation before regulations creating the scheme can be introduced. That consultation ran from September to October 2023 and drew 11,848 responses, and the Department of Health and Social Care published its response on the licensing of non-surgical cosmetic procedures on 7 August 2025.

The most recent clear statement of the timetable came in a written answer of 12 January 2026 from health minister Karin Smyth. It set out the Government’s sequencing: the first priority is legal restrictions bringing the highest-risk procedures under Care Quality Commission regulation so that only specified regulated healthcare professionals may perform them; a licensing scheme for lower-risk procedures would follow under the Health and Care Act powers, administered by local authorities and licensing both practitioners and premises; age restrictions are also planned. Crucially, the answer confirmed that all of this requires secondary legislation and must therefore pass through Parliament, and that the Department intended to consult on restrictions for the highest-risk procedures “in the spring”.

Practitioners should read that carefully. As of mid-October 2026, nothing in the published record indicates that licensing regulations have been made. Any training provider, insurer or supplier telling you that a licence is required now in England is describing a proposal, not a legal duty.

The three-tier model as proposed

The August 2025 consultation response proposed a traffic-light structure, and it remains the clearest published description of the intended shape of the scheme:

• Green — lowest risk, with examples including micropigmentation, intense pulsed light and LED. Open to any practitioner meeting agreed standards.
• Amber — medium risk, with botulinum toxin and semi-permanent facial fillers given as examples. Non-healthcare practitioners would need a licence and a named regulated supervisor; regulated healthcare professionals could work independently.
• Red — highest risk, including procedures augmenting the breast, buttocks or genitals with fillers. Restricted to regulated healthcare professionals, under CQC regulation, in CQC-registered premises.

The House of Commons Library briefing on the regulation of non-surgical cosmetic procedures, published 10 September 2025, remains the most useful single document for the legislative background. Treat the tier allocations in it as proposals subject to change until regulations are laid.

Scotland has legislated first

On 17 March 2026 the Scottish Government announced that the Scottish Parliament had passed the Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Bill. The Scottish Government’s statement on making non-surgical procedures safer records that higher-risk procedures will have to be carried out by, or alongside, certain healthcare professionals in a registered setting, and that procedures cannot be performed on people under 18. Healthcare Improvement Scotland gains power to inspect premises where there are reasonable grounds to believe an offence is being committed.

On timing, Public Health Minister Jenni Minto was explicit that “the offences in the Bill cannot come into force before September 2027”, giving businesses a defined window to adapt. The Royal College of Nursing’s report on the Bill, dated 18 March 2026, adds that the professionals named include registered nurses who are independent prescribers, that Ministers may set training and qualification requirements, and that providing a procedure outside permitted premises is an offence.

For practitioners working across the border, this is now a planning problem rather than a theoretical one: the Scottish premises requirement has no current English equivalent.

Under-18s: the restriction that already exists

It is worth separating the proposed age restrictions from the one already in force. The Botulinum Toxin and Cosmetic Fillers (Children) Act 2021 made it an offence in England to administer botulinum toxin or dermal fillers to under-18s for cosmetic purposes, with an exception where there is a medical need and the procedure is carried out by a qualified healthcare professional. That is existing law, not a proposal. The additional age provisions described in the 2025 consultation response would sit on top of it.

The MHRA’s July 2026 warning on iatrogenic botulism

The most significant practice-level development of 2026 is clinical rather than structural. On 15 July 2026 the MHRA published a Drug Safety Update, botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism. Its key points for practitioners:

• Iatrogenic botulism has been rarely reported after botulinum toxin use, and product information for UK-authorised botulinum toxin type A products is being updated to carry a warning about it.
• New and existing patients should be advised about botulism symptoms — including drooping eyelids, slurred speech and trouble breathing or swallowing — and told to treat these as a medical emergency.
• Symptoms typically appear four to eight days after treatment but can take up to four weeks.
• Risk may be higher with underlying disorders, high doses, off-label use, administration into unapproved sites, or counterfeit or unauthorised products.
• Practitioners should confirm the product is authorised and follow its product information for administration, dose and indication, and should report suspected reactions through the Yellow Card scheme.

The accompanying MHRA and UKHSA news item of 15 July 2026 confirms that the MHRA’s Criminal Enforcement Unit has launched a number of investigations linked to unlicensed botulinum toxin products, following a spike in hospital admissions. Botulinum toxins remain prescription-only medicines in the UK and may only be supplied against a prescription from an appropriate prescriber.

The context is the 2025 outbreak. UKHSA’s warning over botulism, first published 18 July 2025 and last updated 7 August 2025, recorded 41 clinically confirmed cases of iatrogenic botulism reported between 4 June and 6 August 2025, across the North East, East Midlands, East of England, North West, and Yorkshire and Humber, with evidence at that point suggesting an unlicensed product had been used.

What this means for documentation

Three practical implications follow from the October 2026 position. First, product provenance is now an auditable part of practice: records should show the authorised product, batch and source. Second, consent and aftercare materials should name botulism symptoms and the up-to-four-week window explicitly, because the MHRA has now framed that as expected patient information. Third, anyone planning a business model around supervision arrangements in England should treat tier definitions as unsettled until regulations appear.

Frequently asked questions

Is a licence required to administer botulinum toxin in England as of October 2026? No. The power to create a licensing scheme exists in section 180 of the Health and Care Act 2022, and the Government published its policy intentions in August 2025, but the scheme requires secondary legislation that had not been made as of mid-October 2026.

When do Scotland’s new rules start applying? The Scottish Government has stated that the offences in the Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Bill cannot come into force before September 2027.

Are dermal fillers regulated as medical devices in the UK? The Commons Library briefing of September 2025 records that the MHRA consulted in 2021 on extending medical device regulation to products without a medical purpose, including dermal fillers, responded in June 2022 saying it intended to proceed, and had not implemented this. Check the MHRA’s current guidance before relying on any position here.

Where should a suspected case of iatrogenic botulism be reported? Through the Yellow Card scheme, via the website, the app or supported clinical IT systems. The MHRA’s July 2026 Drug Safety Update also directs clinicians to UKHSA guidance on the clinical management of iatrogenic botulism.